Predictive algorithms for adjuvant therapy: TransATAC

Mitch Dowsett; Janine Salter; Lila Zabaglo; Elizabeth Mallon; Antony Howell; Aman U. Buzdar; John Forbes; S. Pineda; Jack Cuzick

doi:10.1016/j.steroids.2011.02.032

Predictive algorithms for adjuvant therapy: TransATAC

Mitch Dowsett, Janine Salter, Lila Zabaglo, Elizabeth Mallon, Antony Howell, Aman U. Buzdar, John Forbes, S. Pineda, Jack Cuzick

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome.

Original language	English (US)
Pages (from-to)	777-780
Number of pages	4
Journal	Steroids
Volume	76
Issue number	8
DOIs	https://doi.org/10.1016/j.steroids.2011.02.032
State	Published - Jul 2011

Keywords

Aromatase inhibitor
Endocrine therapy
Predictive algorithm

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Endocrinology
Pharmacology
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/j.steroids.2011.02.032

Cite this

@article{63ba69caec3040cc90db141ba7f23742,

title = "Predictive algorithms for adjuvant therapy: TransATAC",

abstract = "Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome.",

keywords = "Aromatase inhibitor, Endocrine therapy, Predictive algorithm",

author = "Mitch Dowsett and Janine Salter and Lila Zabaglo and Elizabeth Mallon and Antony Howell and Buzdar, {Aman U.} and John Forbes and S. Pineda and Jack Cuzick",

note = "Funding Information: This work was funded by Breakthrough Breast Cancer and AstraZeneca . The Royal Marsden Hospital receives funding as a NIHR Biomedical Research Centre.",

year = "2011",

month = jul,

doi = "10.1016/j.steroids.2011.02.032",

language = "English (US)",

volume = "76",

pages = "777--780",

journal = "Steroids",

issn = "0039-128X",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Predictive algorithms for adjuvant therapy

T2 - TransATAC

AU - Dowsett, Mitch

AU - Salter, Janine

AU - Zabaglo, Lila

AU - Mallon, Elizabeth

AU - Howell, Antony

AU - Buzdar, Aman U.

AU - Forbes, John

AU - Pineda, S.

AU - Cuzick, Jack

N1 - Funding Information: This work was funded by Breakthrough Breast Cancer and AstraZeneca . The Royal Marsden Hospital receives funding as a NIHR Biomedical Research Centre.

PY - 2011/7

Y1 - 2011/7

N2 - Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome.

AB - Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes. Prediction of the likely course of the disease aids treatment decision-making. In the translational arm of the ATAC (anastrozole or tamoxifen alone or combined) trial (TransATAC) we have assessed individual and multiparameter biomarkers for their prediction of overall and distant recurrence. None of the biomarkers identified differential benefit for anastrozole versus tamoxifen. Each of ER, PgR, HER2 and Ki67 was associated with risk of recurrence. A combination of these to create a single predictor IHC4 was as informative as the 21-gene recurrence score (RS). Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome.

KW - Aromatase inhibitor

KW - Endocrine therapy

KW - Predictive algorithm

UR - http://www.scopus.com/inward/record.url?scp=79958772865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958772865&partnerID=8YFLogxK

U2 - 10.1016/j.steroids.2011.02.032

DO - 10.1016/j.steroids.2011.02.032

M3 - Article

C2 - 21470560

AN - SCOPUS:79958772865

SN - 0039-128X

VL - 76

SP - 777

EP - 780

JO - Steroids

JF - Steroids

IS - 8

ER -

Predictive algorithms for adjuvant therapy: TransATAC

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this